Congressional Report Suggests Ways to Cut Insulin Prices

The Congressional Diabetes Caucus called on policymakers to take steps to bring down insulin prices, including requiring insulin manufacturers and pharmacy benefit managers to disclose rebate details.

The caucus, a bipartisan group of nearly 300 House members, made 11 policy recommendations in a report released by co-chairs Reps. Diana De Gette (D-Colo.) and Tom Reed (R-N.Y.). They include measures encouraging the use of value-based contracts between PBMs and insulin manufacturers, such as directing the Centers for Medicare and Medicaid Services to pilot outcomes-based pricing arrangements in Medicare.

Lawmakers should consider requiring insulin manufacturers, PBMs and federal insurers’ drug plans to disclose their use of rebates, the caucus said.